Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis

(2010) Ana-Carolina Cardoso et al.   JOURNAL OF HEPATOLOGY

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

(2010) Mosaburo Kainuma   WORLD JOURNAL OF GASTROENTEROLOGY

Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance

(2009) F. Benini et al.   DIGESTIVE AND LIVER DISEASE

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

(2009) Alessandro Grasso et al.   JOURNAL OF HEPATOLOGY

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

(2009) Calogero Cammà et al.   JOURNAL OF HEPATOLOGY

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

(2008) Véronique Loustaud-Ratti et al.   HEPATOLOGY

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

(2008) D. Aguilar Marucco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

(2008) J. Morello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group

(2008) Norihiro Furusyo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY